Across immunotherapy, cell therapy, and metabolic disease, the same commercial question keeps surfacing: which patients respond, which can step down or stop, and which need escalation before failure shows up in the data. We apply a structured four-gate stratification framework to translate causal genomics and functional variant science into a commercial thesis biopharma teams can act on.
The business case: faster time to revenue, stronger physician and payer adoption, and a cleaner readiness story for Series B or strategic partnership conversations.
The weighting shifts by modality, but the structure holds: does the patient's biology support response, does the surrounding tissue or immune environment cooperate, does the benefit hold up over time, and can the treatment be delivered and withdrawn safely.
Will this patient's biology sustain a durable response, or does the mechanism need reinforcement to work at all?
Is the surrounding tissue, microenvironment, or metabolic context permissive or hostile to the intended effect?
Does the benefit hold over the long run, or does resistance, relapse, or target loss emerge — and when?
Can the therapy be dosed, tapered, or discontinued safely, and does the delivery model hold up operationally?
Seven therapeutic contexts where a structured stratification thesis changes the commercial conversation — from patient selection to payer economics.
Dual checkpoint blockade regimens outperform monotherapy for some patients but carry meaningfully higher toxicity for all of them. No validated biomarker separates who needs the combination from who doesn't.
Primary gates: A · C
Commercial angle: precision de-escalation to monotherapy where safe, preserving efficacy while cutting toxicity-driven cost and hospitalization.
FDA approval: Opdivo + Yervoy, 1L MSI-H/dMMR mCRC · Trial: André et al., Lancet, 2025 (CheckMate 8HW)
Durable remission depends on T-cell persistence, tumor microenvironment resistance, antigen retention, and manufacturing safety all at once — the one setting where all four gates carry equal weight.
Primary gates: A · B · C · D
Commercial angle: shifting durable remission rates upward directly reshapes the cost-effectiveness case for a therapy priced per infusion.
FDA approval: Breyanzi, first CAR T for marginal zone lymphoma · Durability data: Neelapu et al., Blood, 2023 (ZUMA-1, 5-yr follow-up)
Response and resistance both track closely with variant-level biology, and a meaningful share of patients lose response within a few years — with no structured way to anticipate it.
Primary gates: A · C · D
Commercial angle: converting empiric dose escalation into biomarker-guided treatment optimization extends franchise value against generic and next-gen pressure.
FDA approval: Ojjaara (momelotinib), 2023 · Variant biology: Patel et al., Blood, 2015
Efficacy depends entirely on the fitness of the patient's own T cells to be redirected — a dimension current diagnostics measure only crudely.
Primary gates: A · C
Commercial angle: a T-cell fitness thesis supports premium positioning against CAR-T and improves patient selection for an emerging drug class.
FDA approval: Tecvayli + Darzalex Faspro, 1L+ RRMM · Fitness biology: Cortes-Selva et al., Blood, 2024 (MajesTEC-1)
The shift from anti-TNF to targeted cytokine blockade (e.g., IL-23) raises a first-line question: which patients are driven by the targeted pathway versus a different one entirely.
Primary gates: A · B
Commercial angle: a pathway-dependence thesis positions targeted cytokine therapy as a precision-selected first-line option rather than a trial-and-error step.
FDA approval: Icotyde (icotrokinra), first oral IL-23R blocker, 2026 · Pathway biomarkers: Cantó et al., Int J Mol Sci, 2025
A $100B+ incretin therapy market with three unresolved questions: who responds, who can safely discontinue, and when the metabolic shift becomes durable enough to stop.
Primary gates: A · C · D
Commercial angle: a discontinuation-readiness thesis reframes GLP-1RA therapy from an indefinite commitment into a precision intervention with a defined endpoint — the single biggest lever on payer economics in the category.
FDA approval: Foundayo (orforglipron), first small-molecule oral GLP-1, 2026 · Discontinuation data: Wilding et al., Diabetes Obes Metab, 2022 (STEP 1 extension)
RAS mutations drive roughly 90% of pancreatic adenocarcinomas and a meaningful share of colorectal and lung cancers, but the target was considered undruggable for decades — leaving patient selection and resistance tracking largely unaddressed as the first approved agents reach the clinic.
Primary gates: A · C
Commercial angle: converting an undruggable-target narrative into a biomarker-selected franchise reframes RAS inhibition from a last-line option to a stratified first-line thesis.
FDA approval: Rasonque (daraxonrasib), Aug. 2026 · Emerging approach: Biswas et al., Immunity, 2023
A commercial translation model for genomics platforms and biopharma teams building patient stratification into their next therapeutic program.